Onesource Specialty Pharma Limited (ONESOURCE) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Onesource Specialty Pharma faces a critical Q1 as it balances a major capacity expansion with the need to accelerate revenue toward its FY28 target of $400M. Investors will be looking for signs of sustained margin recovery and cash flow improvement following a volatile FY26 marked by heavy capital expenditure and rising debt.

Onesource Specialty Pharma Limited Q1 Results Date and Time

The company has scheduled a board meeting for July 24, 2026, to consider the audited financial results.

What to expect from Onesource Specialty Pharma Limited's Q1 FY27 results

The company enters Q1 FY27 building on the Q4 FY26 revenue recovery of Rs. 428.2 Cr, with a 9–11% weaker rupee providing a material translation tailwind for USD-denominated export revenues compared to the year-ago period. While Q4 EBITDA margins improved to ~22.4% from the Q3 trough of 6%, management faces the challenge of bridging the gap to the year-ago Q1 FY26 margin of 28.6% amid elevated depreciation costs of Rs. 71.8 Cr per quarter. Sustaining the positive PAT of Rs. 4.6 Cr achieved in Q4 will depend on managing the high working capital intensity, which saw inventories reach Rs. 439 Cr and trade receivables hit Rs. 690 Cr by the end of FY26. The upcoming call will likely focus on the order book trajectory required to meet the FY28 organic revenue target of $400M and the impact of the ongoing 200M-vial capacity expansion on the company's Rs. 1,240.6 Cr net debt position.

Key Things To Watch

Order book and revenue growth: Monitoring the sustainability of the sequential recovery seen in Q4.

• Sequential growth trends and composition of the order book across biologics and small molecules.
• Visibility on the FY28 $400M organic revenue target, which implies a 55% CAGR from FY26 levels.

EBITDA margin and FX impact: Assessing the bridge between current margins and the 28.6% level seen in Q1 FY26.

• Impact of the 9–11% INR depreciation on export revenue translation and realized rates.
• Operating leverage on fixed costs versus the drag from inventory carrying costs and Rs. 71.8 Cr quarterly depreciation.

Capex and debt trajectory: Managing the financial burden of the ongoing capacity expansion.

• Status of the 200M-vial capacity expansion and movement in CWIP, which rose 420% YoY to Rs. 313.9 Cr.
• Changes to the borrowing program given total borrowings rose 46% to Rs. 1,276 Cr in FY26.

Risks and headwinds to monitor: Key external factors impacting the balance sheet.

• Prestige litigation contingent liability of USD 136.3M, equivalent to approximately Rs. 1,286 Cr.
• Working capital intensity with a cash conversion cycle of approximately 194 days.